Owen Siggs
@osiggs.bsky.social
Lab Head and Program Director, Garvan Institute of Medical Research
Reposted by Owen Siggs
Regeneron Pharmaceuticals said it will acquire substantially all of 23andMe’s assets for $256 million after coming out on top at a bankruptcy auction for the once-sizzling DNA-testing startup
Regeneron to Buy 23andMe Out of Bankruptcy for $256 Million
Regeneron Pharmaceuticals said it will acquire substantially all of 23andMe’s assets for $256 million after coming out on top at a bankruptcy auction for the once-sizzling DNA-testing startup.
buff.ly
May 19, 2025 at 12:15 PM
Regeneron Pharmaceuticals said it will acquire substantially all of 23andMe’s assets for $256 million after coming out on top at a bankruptcy auction for the once-sizzling DNA-testing startup
Reposted by Owen Siggs
Very excited to share our preprint led by M. Levin @skoyama.bsky.social J. Woerner & with S. Damrauer assessing genome-wide pleiotropy of >1,000 clinical traits across ~1.7M individuals with nearly 30K locus-trait associations!
www.medrxiv.org/content/10.1... @medrxivpreprint.bsky.social
www.medrxiv.org/content/10.1... @medrxivpreprint.bsky.social
April 23, 2025 at 11:35 AM
Very excited to share our preprint led by M. Levin @skoyama.bsky.social J. Woerner & with S. Damrauer assessing genome-wide pleiotropy of >1,000 clinical traits across ~1.7M individuals with nearly 30K locus-trait associations!
www.medrxiv.org/content/10.1... @medrxivpreprint.bsky.social
www.medrxiv.org/content/10.1... @medrxivpreprint.bsky.social
Reposted by Owen Siggs
A high polygenic risk score (PRS) for screening prostate cancer was superior to a PSA test or MRI for detecting clinically significant disease (Gleason ≥7). A big step forward for supporting utility of PRS @nejm.org
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Assessment of a Polygenic Risk Score in Screening for Prostate Cancer | NEJM
The incidence of prostate cancer is increasing. Screening with an assay of prostate-specific
antigen (PSA) has a high rate for false positive results. Genomewide association studies
have identified...
www.nejm.org
April 9, 2025 at 9:25 PM
A high polygenic risk score (PRS) for screening prostate cancer was superior to a PSA test or MRI for detecting clinically significant disease (Gleason ≥7). A big step forward for supporting utility of PRS @nejm.org
www.nejm.org/doi/full/10....
www.nejm.org/doi/full/10....
Reposted by Owen Siggs
I chatted to @stuartbuck.bsky.social about scientific funding in the US and Australia, organisational incentives, institutional senescence, and the joy of seeing other researchers doing clever things with data you released: goodscience.substack.com/p/interview-...
Interview with Daniel MacArthur
This is an interview with Daniel MacArthur, whom I first met when he was at Harvard Medical School, Massachusetts General Hospital, and the Broad Institute of MIT and Harvard in Boston.
goodscience.substack.com
December 3, 2024 at 10:32 PM
I chatted to @stuartbuck.bsky.social about scientific funding in the US and Australia, organisational incentives, institutional senescence, and the joy of seeing other researchers doing clever things with data you released: goodscience.substack.com/p/interview-...